Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jerry, At 11:40am, there was a 3 minute span that the price went from 1.05 to .87 on approx. 55k shares. Obviously mostly sells. It was never really able to recover from there. A while after the drop, I had an order in for 6 minutes at .91, on a .91 to .94 spread, but cancelled after it wouldn't execute. Cor is still acting hard to exit, even on this relatively "high volume" day.
Take Care.
Was able to add to two IRA's today on the dip. Only 12,000 or so shares sent it down from .49 to .46 late. (15:31 to 15:45) Buyers dried up. Today's volume only 15k more than 3 month average, so nothing special there. (237,676.)
Take Care.
surf, are you thinking history repeats in here, or do you think there are longer legs this time around?
also, in those past years, do you know if small bio tracked similarly, or did they peak before or after?
ot- vnda spike, on volume, exit?
thanks
Thanks Surf, I only have a small 5k share position as I had just started adding the last couple days, most all of the shares at the bid.
I am showing it as last trade at .42, but that must have been after hours last night???? I show no volume yet this morning.
OT- Nuvo looks like it is trying to open higher.....
Thanks for keeping all these boards going!
Form 8-K for ACUSPHERE INC
""""scstocks here- Another success at putting off payments until after the FDA decision. IMO, a lot of these delayed payment arrangements that ACUS is getting shows that their creditors certainly think they will be around after the FDA decision. I mean why let ACUS extend credit, when they know that ACUS has the funds now, and they could force them to pay, but choose to let the the payments owed ride until after the FDA decision? They must have faith..... and so do I, and I did add some today on the dip.""""end scstocks""""
http://biz.yahoo.com/e/080729/acus8-k.html
--------------------------------------------------------------------------------
29-Jul-2008
Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Item 1.01 Entry into a Material Definitive Agreement.
On July 29, 2008, Acusphere, Inc. (the "Company") entered into an amendment (the "Amendment") to the Patent License Agreement (the "Agreement") by and between the Company and Bracco International BV ("Bracco") dated as of June 1, 2006, as previously filed with the Securities and Exchange Commission (the "SEC") with the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2006. Under the Agreement, the Company was obligated to make a payment of Euro 500,000 to Bracco within five business days after the acceptance by the US Food and Drug Administration ("FDA") of a new drug application filing package for the Company's lead product candidate, Imagify� (Perflubutane Polymer Microspheres for Injectable Suspension). The FDA accepted the Company's application on June 30, 2008, making such payment to Bracco due on July 8, 2008. The Amendment reduces the amount of the payment due on July 8, 2008 to Euro 100,000, and provides that an additional payment of Euro 400,000 will be due on the first anniversary of such acceptance by the FDA, or June 30, 2009. The Amendment further provides that the Company grants Bracco a perpetual non-exclusive and royalty-free right and license within the field of ultrasound diagnostic imaging to use and exploit any intellectual property that the Company has developed or may develop after June 1, 2006 which relates to, or to the use or performance of, the patents licensed by Bracco under the Agreement. The other terms of the Agreement are otherwise unchanged.
The above summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which has been filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated into this Item 1.01 by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
10.1 Amendment to Patent License Agreement by and between the Company and
Bracco International BV, dated as of July 29, 2008
I listened to the call and liked what I heard.
They must be getting fire sale offers and are trying to show that they are willing to go to the mat with Imagify to strengthen their position. Even take salary cuts to extend the time of needed financing, and to lower the amount needed if and when that time comes.
The FDA dept. that is reviewing their NDA, recently approved a different contrast agent for a different end use.
But my favorite part of the call was when Zacks called in, and about 24:10 into the call, the CEO, (I think that is who was speaking,) talked about the FDA public hearing on contrast agents from June. Imagify was not on the agenda, as the NDA had not yet been approved, but she said that After "impassioned" remarks about the life saving potential from those in the audience, and the uncertainties of the radioactive contrast agents out there, the consumer representative from the FDA panel, indicated that given what else was out there, they would certainly be open to a new, safer, contrast agent. (I paraphrased that as best I could after just one listen, so I highly recommend that you listen for yourself in case I messed up a detail or two.) Anyway, like I said, I liked what I heard.
I mean think about if you and your firm are interested in Imagify, and you were trying to get the best terms you could for a possible 2 BILLION YEARLY MARKET drug that already had spent so much money getting through phase III, gathering data on 1000 patients, and getting the NDA approved. You think you have Acusphere over a barrel, and now Acusphere is showing some backbone in trying to get to the endzone without help, or as little as possible.
It is true every day that Acusphere waits, the more cash they use, but also it is a day that someone else could sow up a drug with a 2 BILLION dollar potential market, only months away from hearing from the FDA, and shutting out all other interested parties. Those kind of markets, for a drug this far along, don't grow on trees, and I am glad that management has taken this road, rather than give away the store. You have to play hardball when the going gets rough, and that is what they are trying to do, imho.
I will be adding to my position on any weakness going forward, and it's getting pretty big, for me, now.
Anyone interested can hear the call here:
http://investor.acusphere.com/eventdetail.cfm?EventID=57811
The analyst from Zacks, Jason Napodano, ranks number 39 on this tip site, jim cramer of "mad money" ranks 96.
http://tipstraders.com/tipsters.php?l=100&r1=s&r2=t&rdr=desc
GLTU
Still HUGE premarket, 3.5 million with 45 minutes to go.
have seen several 50k at 1.50
a 100k at 1.50
a 200k at 1.49
an 83k at 1.48
they just keep flying by......
not that many shares out in this one, this is heavy volume for its size.....
some HUGE orders going through right now, a little over an hour before the open.....2.5 million shares....1.45 low so far that i have seen.
Vanda schizophrenia drug rejected by FDA
Monday July 28, 7:47 am ET
FDA rejects Vanda Pharmaceuticals' experimental schizophrenia drug, shares fall 50 percent
http://biz.yahoo.com/ap/080728/vanda_pharmaceuticals_fda.html?.v=1
ROCKVILLE, Md. (AP) -- Vanda Pharmaceuticals Inc. said Monday the Food and Drug Administration rejected the biotechnology company's experimental schizophrenia drug iloperidone, saying it was similar to drugs already on the market.
ADVERTISEMENT
Shares of Vanda lost about half their value in premarket trading on the news.
The agency wants the company to conduct additional studies on the drug, including a comparison with currently marketed treatments, such as Johnson & Johnson's Risperdal or Eli Lilly & Co.'s Zyprexa. In prior studies, the drug was more effective than placebo, but only similarly effective when compared with Pfizer Inc.'s ziprasidone.
Also, additional safety data would be needed to consider another application.
"We are disappointed by this response, but will meet with the FDA to discuss this decision further," said Vanda President and Chief Executive Dr. Mihael H. Polymeropoulos in a statement.
Vanda said all iloperidone-related activities are on hold pending further review.
Shares of Vanda dropped to $1.67 in premarket trading from a $3.36 close Friday.
Thanks justsotb,
I had forgotten the r/s date as I hadn't traded cor for a while back then. I was on the road a lot in '95. I actually thought it might have been a little later in the 90's, so my mind is not as sharp as it once was! (for sure)
Humm, If a stock has a regular 2 for 1 split, then the price is reflected accurately on the next days chart, opening at half the previous days close, because the shares out are twice as many. The chart before that time remains unchanged, or so I think. So in my mind it makes sense that cortex's chart should be reporting exact prices pre-split, be it forward, or reverse. Obviously I am not a chartist, but I do enjoy looking at them, mostly just price and volume of recent days/weeks. I used to manually scan a couple thousand a night with livewire professional software that only worked with the DOS operating system. Made some decent money back then just looking for a spike in volume and often higher prices would follow. (sort of caveman t/a i suppose.)
Not positive, but don't think cortex traded near 4.20 in '92, and I know there was a company trading under "cor" around that time because I used to see it all the time in the paper, while looking for a cortex quote. It was "cor," then "corx" in the paper every day. I think that msn may have just picked up the old cor prices, that were not cortex. I traded corx many times pre 1992 around .36, and the msn chart does not come close.
http://moneycentral.msn.com/investor/charts/chartdl.aspx?D4=1&ViewType=0&DateRangeForm=1&ComparisonsForm=1&D5=0&ShowChtBt=Refresh+Chart&D3=0&CE=0&Symbol=COR&C9=0&DisplayForm=1&CP=0&PT=11
That being said, I did find some old broker statements from '92, but they were from centocor leaps, cifra, (a mexican retailer that was going in with walmart at that time,) and a company called biomedical waste systems. No cortex receipts so I am not sure about my .50 price, but that sticks in my head.
Mostly I was wondering if others have had experiences where they were pretty sure the data from a chart they were looking at was not correct. I think a lot of us just assume that the data we get is accurate. I am thinking of a "new" investor that might see that cortex "once" traded near 21, so hope springs eternal, and dives in, based on false info. (as bad as that sounds, I have done it in my day, jumped in a stock because it had previously hit a much higher number.)
Anyway, I surprise myself how often I am wrong, so if someone can help with the way a reverse split stock chart shows prices before the split took place, please either reinforce what justsotb wrote, or offer up another explanation.
Thanks again.
Hello Dew, I just got an email from my brother.
He was writing about Cortex while referring to a chart from msn's money site. In his email he was talking about cor being 21 dollars back in 1992. (chart set to max.)
I thought to myself, "I owned cortex in 1992 and I thought it was around 50 cents or so," but that is from memory. But for sure Cortex traded as "corx" back then.
I think what MSN has done is just taken the symbol "cor" and combined it with a stock trading as COR back in 1992, which would not have been Cortex Pharmaceuticals.
I am curious if you, or others, have run into this issue before with MSN, or other sites, and if so, how often?
Take Care.
Dr. Herbert Hurwitz Joins Scientific Advisory Board At Threshold
Thursday July 24, 8:00 am ET
http://biz.yahoo.com/pz/080724/146971.html
REDWOOD CITY, Calif., July 24, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NasdaqCM:THLD - News), today announced that Herbert Hurwitz, M.D. has joined the Company's Scientific Advisory Board (SAB). Dr. Hurwitz is an Associate Professor of Medicine at Duke University Medical Center and a medical oncologist at the Duke Comprehensive Cancer Center.
ADVERTISEMENT
``Tumor hypoxia is a promising area that is gaining a great deal of attention among the medical research community,'' said Herbert Hurwitz, M.D. ``I am pleased to be a member of Threshold's Scientific Advisory Board and look forward to working with Threshold scientists and clinicians as well as the investigators who are conducting the early clinical trials.''
``We are extremely pleased that Dr. Hurwitz will be on the SAB and a consultant to Threshold,'' said John Curd, M.D., chief medical officer. ``His knowledge and experience in developing early and late-stage cancer therapeutics will provide a great deal of insight into the development of our hypoxia-activated prodrugs. Dr. Hurwitz has extensive understanding of hypoxia and angiogenesis which, when combined with his experience in oncology drug development, will add significantly to the development of TH-302, our hypoxia-activated prodrug currently in a Phase 1 clinical trial for the treatment of solid tumors.''
Dr. Hurwitz has clinical expertise in Phase 1 clinical trials involving new anti-cancer drugs, drug combinations, and combinations of new drugs with radiation and cancers of the gastrointestinal system. His particular interest is in biomarkers related to anti-angiogenesis therapy. He was the lead author on the IFL/bevacizumab study in colorectal cancer. He is associate professor of medicine and the clinical director of the Phase 1 program and co-leader of the GI Oncology program at Duke University Medical Center in Durham, North Carolina.
Dr. Hurwitz received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania, and completed an Internal Medicine residency at Michael Reese Hospital in Chicago, Illinois, and an Oncology fellowship at Johns Hopkins Oncology Center in Baltimore, Maryland. He is an author of over 50 peer-reviewed scientific papers published in leading journals.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (http://www.thresholdpharm.com).
Contact:
Threshold Pharmaceuticals, Inc.
Denise T. Powell, Sr. Director, Corporate Communications
650-474-8206
dpowell@thresholdpharm.com
--------------------------------------------------------------------------------
Source: Threshold Pharmaceuticals, Inc.
hello surf, any interest in this one down in here? i noticed that you had posted on it for a while, and maybe even moderated??? i don't track it, but just put it on radar.
take care.
Agreed, I began another position a couple days ago, and quadrupled down today.
OT, is there an event coming in nuvo?
Take Care.
Thanks Dew, Do you a feel for how much money we are talking about? 5 Billion, 50 Billion????? I have no clue other than there is a ton of money in index funds and bio funds....
I suppose I could just look it up and see how much fund money is in it now and do my own DD, but then you are that name
Take Care.
Morning gfp, Those large bid/asks you sometimes see are often just head fakes put out there my market makers/players that want a stock to "appear" one way or another, showing strength, or weakness, depending on current action. I have seen them for years in many stocks, including last week at least 3 I saw with my own eyes.... in one case a 9300 share ask would appear, and then disappear as soon as I put an order in... then within a few minutes it would reappear. This happened for hours.
Cor had 5300 shares total traded this morning and the price after 5300 shares was .83, then after 7500 shares total traded for the day, they were back at .92. Pretty big swing and once again, imo, showing that it would be very difficult to exit in this environment without getting hurt.
I like looking at charts, and have done so since before there was a windows 3.0, but all the charts in the world, again jmo, won't show you how a thinly traded stock is really trading until you start watching the orders going in and out. Charts are great, but making REAL money means going up against humans, and gauging if you can get a big enough position, in and OUT to make it worth your while in that given trading environment.
OT, surf posted on his hotbiotechs board this morning that all of the fund money that was in genentec, will have to be redistributed among the remaining bio's, as roche is not considered a bio, hence the need for redistribution. If it is a biotech fund then likely they have limits and rules about sticking mostly with bios, so it makes sense that the money would have to find a new home should roche be successful. Might be a plus for big bio shares.
Might be great morning for biotech this morning thanks to Roche. I am showing pre market, on NO SHARES TRADED:
NRGN +.0514 (12.85%)
NUVO + .3599 (66.64%)
VNDA + .0882 (2.53%)
There are a bunch more. Been a while since I remember this many before the open looking like they might get pushed....
GLTU today!
Yikes, that was REALLY fast! Thanks surf.
Take Care.
Hello surf, I am still buying acus. I was wondering if you have an update from Zacks on this stock? (I don't subscribe, maybe from a free section?) I found this from an acus post last feb:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=26703261
Zack's has a 5 page report dated 2/7/08 By: Jason Napodano.
It has a target of $5!
SUMMARY RECOMMENDATION
Our model below explains quiet simply our stance on Acusphere. We see $2.45 in EPS in 2011 based on $321.5
million in Imagify sales. At the current market capitalization of $30 million, the name represents the most
undervalued story in our entire biotech coverage universe. At this point we are surprised the company has
remained independent. Our only concern is that someone could takeout Acusphere at $50-100 million ($1.50
2.50 / share), and that would be unfair to long-time shareholders that believe in the story and have been waiting
around through difficult times for that day when it all comes together.
It is difficult to say how the FDA will rule on Imagify. We think there is a very good chance the company gets the
drug approved and on the market in early 2009 based on the combined evaluation of the RAMP 1 and 2 data and
the ROC analysis presented by management in late 2007.
thanks florida, actually i have been around since about a month after surf started this board, in and out a few times. not sure if i will hold through event or just the hopeful run up to it next week. seems like plenty would want to take a flyer on it.
liked the post about those that bought in at 20 must have really liked it. i almost bought in at 11 one time, but just watched it.
take care.
Oops, forgot one. I added yesterday...eom
Take Care.
Yikes, Ease up on throttle a little. I for one have enjoyed reading the exchanges between gfp, neruo, and enemem. They understand Cortex in a way I could only hope for.
You are in a fortunate position, and the only person I know that still uses the term, "Dude," that has an extra 250,000 dollars to toss in cor's direction. Also the fact that you know "inside" people at cortex that you can just pick up the phone and openly discuss current events, I mean you are really fortunate.....
I am not sure if free members are able to see every post that every ihub member has ever made, but I can assure you that paying members can.
I see that from your past posts you have attacked, at one time or another, ombostring, enemem, gfp, and Ruengies3. There may be others but I only looked for a minute. Not a bad record for a person that has only posted a TOTAL of 31 times in nearly 2 years. Your posts have added nothing imo, so lighten up on those making an honest stab at evaluating cor's current prospects, and not just singing the ra ra cor tune.....
is nrgn getting interesting again? down .10 at .38..??
Hello patco, I am not sure, but I think he meant that without the treasuries, his account would be down 7.5%+ ??? The 3.5 kicker gave him some breathing room.
Just a guess......
Take Care.
Hello gfp, First let me say thanks to you and all others who have been posting such interesting info on cor lately, even if I only grasp small parts of it. I love learning new things, and learning from different angles, with differing opinions.
I am in oil plays that hope for falling prices, dug and wnr. I tried to bottom fish BAC, Bank of America, and stopped out at 4% down yesterday. At some point I can see myself playing a large bank with good capital and a good dividend, but not now. They are becoming oversold, or are they????? And of course bio's.
I am not currently in cor. I sold out on the last 1.20 spike day of June 4th, when I posted I was lightening up. Actually I thought about it for a minute after I posted and then sold out completely. No news runs have historically been a good place for me to sell cor.
I tried to buy back in at .73 around the 3rd week of June but my orders would not execute and I decided not to chase it. Wish I had chased it a few cents now
I posted recently that cor seems weak to me in here, and i posted a minute and a half worth of consecutive trades to show how it dropped from .97 to .82 on very few relative shares, and VERY quickly. It is what I think of as a classic cor "push," where the price is pushed up artificially and anyone trying to get out has to do so slowly, or get crucified. If you are buying, even relatively small amounts, the price gets "pushed" away from you and really gets pushed if you are trying to get quantity. Hence the move from .82, after a 5k sale, to .89, on a 100 share order. I almost couldn't believe my eyes. Those were consecutive trades in the middle of the day. Wouldn't it be nice if it moved up 8.5% with EVERY 100 share order!!!
I once posted about tossing out 3 consecutive 5k sell orders in cor and they were gobbled up without moving the bid/ask much, if at all. I sign of real strength imo, and cor nearly doubled from there. (It could have even done better than a double, i forget exactly.) Well now the opposite is happening, imo, if you throw some sell orders at cor now, the price seems to plummet very quickly.
Anyway, that's not the kind of action that I like to be in with cor, so I am out for now. I like to buy when the price seems to be being pushed downward. Doesn't mean you can't make money in it if all goes well, and you don't sell out all at once, but I am just not willing to take the risk for now.
While we are at it, take a look at ACUS, they got an NDA on June 30th, they're low on funds, and got a non compliance NASDAQ letter today. Investors are nervous about it. I love them going forward. This nda has a 2 billion dollar market, (according to the acus ihub board, i have also posted dew on his biotech values board and am waiting to hear if he is familiar with acus,) they have been through phase III, they should get a go/no go from the fda by 2/28/09. Of course we all know that may change with more info needed and that kind of thing, but they are pretty far along.
They are that far along and the stock is .53 with 46 million shares out. It didn't pop that much on the NDA approval, so in my mind, it is not written in stone that cor goes through the roof if rd shows proof of concept. It may not budge much, or for long. Or, it may take investors a while to realize that cor has the real deal, given cor's history, should rd go perfectly. And then Cor is still a long long way from phase III being completed, if at all.
Now that I have said all that watch cor come out with great rd results, and as someone I know says, goes to the moon baby!
Take Care.
ps, dew just pm'd that he does not follow acus, so now i have to dig a little deeper. ihub is so great for sharing knowledge. If anyone has any info on market size, other players, even guesses as to fda actions, ect, I would REALLY appreciate any info posted to the ACUS board, thanks.
i just can't trust many stock reports anymore as i never know what their "angle" is. i mean is their firm pushing for the person to lean one way or another because of a stock/option position, or business relationship that impacts the stock, or impacts a person on the board, or is it legit......the list goes on.
i lucked out on this one as i got in at .73-.75, sold 60 some percent at around 1, then the balance at .63-.65. i could have gotten clobbered.
in wnr now as an oil play on falling prices. not too much.
Hello Dew, I was wondering if you have a take on ACUS?
They received an NDA a couple of weeks ago for a cardiovascular drug for the detection of coronary artery disease.
They will need cash soon and received a non compliance letter for having a low stock price from the NASDAQ today.
I didn't see any posts from you over on the ACUS board and wondered if you track it, or are familiar with it, the potential market, or competitors?
Thanks in advance for any help you might provide.
Take Care.
Nice to see that the letter was already built into the price. All these small bio's seem to get a letter at one time or another in their lives, and often they get hit, like it was a surprise. It shouldn't be.
I was a little surprised that this didn't pop more after the NDA was approved. I think it is still under a lot of radars.
Take Care.
Volume up 50+% against full day avg volume already.
Have another order in.
Take Care.
Thanks surf, I already sold remaining at .64. Funny but the sales didn't show on my level II. Might be having slow server problems this morning.
I might play bounce as well.
Take Care.
Sold 60+% of mine last week for no particular reason, just profit taking.
Not sure what to do with remaining shares????
Any thoughts?
must have been some good news during the call last night.
up .10, 19% today.
take care.
Thanks surf, dipped in toes this morning.
Take Care.
Nice open in memy this morning, bump .04, 11%. First time in a while.
Take Care.
humm, if iran shooting off rockets can't sustain an oil rally, maybe it might finally be turning negative????
two weeks ago it that news would have shot oil up 10 bucks.
I am showing a 1.51 a share in cash at the end of march. I read the release for may, but didn't see a cash per share figure, and before digging around any more, I thought I would see if you knew it off the top of your head.
Thanks and take care.
bought more on dip this morning.
Another Small Bio Buyout. Hope for Cor, The Big Boys Need Product..
Eli Lilly to buy SGX Pharmaceuticals for $64M
Tuesday July 8, 5:13 pm ET
Eli Lilly to pay $64 million for SGX Pharmaceuticals in bid to expand biotech efforts
http://biz.yahoo.com/ap/080708/eli_lilly_sgx_acquisition.html?.v=1
NEW YORK (AP) -- Drug developer Eli Lilly and Co. will buy SGX Pharmaceuticals for about $64 million in cash in an effort to expand its drug discovery efforts, the companies said Tuesday.
Indianapolis-based Eli Lilly will pay $3 per share for the San Diego-based biotech company, marking a premium of more than double SGX's closing price of $1.37 Tuesday. The companies have been collaborating since 2003 and the deal will now allow Eli Lilly to expand its biotechnology development platform along with a portfolio of potential cancer treatments.
ADVERTISEMENT
SGX shares quickly jumped to within range of the buyout price in after-hours trading, soaring to $2.87.
"We will leverage the combined resources of both companies to strengthen our structural biology capabilities and seek out innovative therapies for patients," said Steven M. Paul, executive vice president of science and technology for Eli Lilly, in a statement.
Eli Lilly is among several large pharmaceutical companies who have bought biotechnology operations in a bid to expand development pipelines. In November, Kenilworth, N.J.-based Schering-Plough bought Dutch biotech company Organon BioSciences for about $14.43 billion.
Eli Lilly, which sells Byetta for diabetes and Cymbalta for depressive disorder, among other products, said it expects a charge for the SGX buyout, but did not provide an estimate. The deal is expected to close in the second half of 2008 and is still contingent on SGX shareholder approval and antitrust clearance.
"We believe that this merger provides an excellent opportunity for the potential of SGX's platform and pipeline to be realized, while simultaneously providing our shareholders with attractive financial terms," said Mike Grey, SGX's chief executive.
Shares of Eli Lilly rose $2.25, or 4.9 percent, to close at $48.46
Hello surf, are you showing anything on kerx?
some heavy selling today, 1.3 million vs 646k avg.
take care.
thanks cash2, to continue with cor being weak in here:
check out these consecutive trades today, after being up 5 cents on 33k shares earlier:
All at 12:52
100 at .97
100 at .95
100 at .95
200 at .9302
300 at .9002
100 at .90
1000 at .92
300 at .90
100 at .90
200 at .91
200 at .90
100 at .85, huh?
200 at .88
1000 at .89
200 at .87
300 at .87
5000 at .82, only 5k brings it down here???
100 at .82
400 at .82
2400 at .82,
then at 12:53
100 at .89, really???? from .82 to .89 on 100 shares????
2400 at .8601,
from then on it is mostly very small orders pushing it back up to .94 by 13:44.
if I was selling into this, it would be slowly, small orders, over days.
take care.
OT: thanks cash2, I should have specified. still, i think of it as a bet on falling oil.... here is a tidbit from proshares website:
"""""Objective
UltraShort Oil & Gas ProShares seeks daily investment results, before fees and expenses, that correspond to twice (200%) the inverse (opposite) of the daily performance of the Dow Jones U.S. Oil & Gas IndexSM."""""
http://www.proshares.com/funds/dug.html
there are days when dug moves in the same direction as oil, but in my experience, they move apart overall.
i have been in and out of it many times this year, overall it's been good to me, but i sell it quick if i am down just 2 or 3 percent as i try to conserve capital, then try again. this time around has been a good run for sure. either oil breaks at some point, or the world economy goes belly up imo.
take care.